GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
GLP-1/glucagon dual receptor agonists showed a higher likelihood of MASH resolution and significant reductions in liver fat, but gastrointestinal side effects were more common.
Where it sits
this study against the rest of the pemvidutide corpusSummary and findings
This systematic review and meta-analysis evaluated the effects of GLP-1/glucagon dual receptor agonists on metabolic dysfunction-associated steatohepatitis (MASH) in adults. Four trials involving a total of 673 participants were analyzed. The results indicated an increase in MASH resolution and reductions in liver fat and liver enzymes, but also noted an increase in gastrointestinal adverse events.
Abstract
<h4>Background</h4>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with high unmet therapeutic need. GLP-1/glucagon dual receptor agonists are an emerging drug class, but no meta-analysis has evaluated it exclusively.<h4>Methods</h4>In this registered systematic review and meta-analysis (PROSPERO CRD420261325731), we searched PubMed, Embase, Cochrane, and Google Scholar through January 2026 for placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. Four trials (survodutide, pemvidutide, cotadutide; n=673) were pooled with DerSimonian-Laird random-effects models; Hartung-Knapp-Sidik-Jonkman adjustment was a sensitivity analysis.<h4>Results</h4>Dual agonists increased MASH resolution without worsening of fibrosis (RR 2.98, 95% CI 2.09-4.24; k=2). A borderline, exploratory signal for fibrosis improvement was observed (RR 1.38, 95% CI 1.01-1.88; p=0.044; k=2); neither trial was individually significant. Relative liver fat fell by 46.24% (95% CI -55.24 to -37.24), and ≥30% liver fat reduction was more frequent (RR 4.39, 95% CI 2.97-6.49). ALT (MD -20.38 IU/L, 95% CI -33.00 to -7.75), AST (MD -18.80 IU/L), body weight (MD -4.36%) and systolic blood pressure (MD -5.22 mmHg) decreased; the ELF reduction was not retained in sensitivity analyses. Nausea (RR 2.90), vomiting (RR 9.58) and diarrhea (RR 1.90) were more frequent; serious adverse events were not (RR 1.06). Split-placebo analyses were consistent.<h4>Conclusions</h4>Dual agonists were associated with a higher likelihood of MASH resolution, a borderline exploratory fibrosis signal, and reductions in liver fat, liver enzymes, weight and systolic blood pressure, with more gastrointestinal adverse events. These early-phase findings support continued Phase 3 evaluation.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.